Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Roche Products Limited
Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW
Telephone: +44 (0)1707 366 000
Fax: +44 (0)1707 338 297
WWW: http://www.rocheuk.com
Medical Information Direct Line: +44 (0)800 328 1629
Medical Information e-mail: medinfo.uk@roche.com
Customer Care direct line: +44 (0)800 731 5711
Medical Information Fax: +44 (0)1707 384555

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 01/09/2011
PIL Tarceva 25mg, 100mg and 150mg Film-Coated Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 01/09/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
  • Changes to therapeutic indications
Updated on 27/05/2011 and displayed until 01/09/2011
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 08/07/2010 and displayed until 27/05/2011
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 05/05/2010 and displayed until 08/07/2010
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Changes to therapeutic indications
  • Change to information for healthcare professionals
Updated on 09/06/2009 and displayed until 05/05/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 18/02/2009 and displayed until 09/06/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 31/10/2008 and displayed until 18/02/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 05/02/2008 and displayed until 31/10/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to date of revision
Updated on 13/08/2007 and displayed until 05/02/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 26/03/2007 and displayed until 13/08/2007
Reasons for adding or updating:
  • Change to date of revision
Updated on 12/02/2007 and displayed until 26/03/2007
Reasons for adding or updating:
  • Change to how the medicine works
  • Change to Further Information section
  • Change to date of revision
Updated on 04/12/2006 and displayed until 12/02/2007
Reasons for adding or updating:
  • Change to side-effects
  • Change to Further Information section
  • Change to date of revision
Updated on 28/03/2006 and displayed until 04/12/2006
Reasons for adding or updating:
  • Change to side-effects
  • Change to warnings or special precautions for use
  • Change to date of revision
Updated on 17/02/2006 and displayed until 28/03/2006
Reasons for adding or updating:
  • Change to Marketing Authorisation Holder
Updated on 23/09/2005 and displayed until 17/02/2006
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  erlotinib hydrochloride